Latest Financial Results News

Argent BioPharma reported a significantly reduced half-year loss of A$2.9 million, progressing a strategic acquisition to bolster its CannEpil drug pipeline and securing up to A$11 million in new funding.

SDI Limited reported a modest 2% dip in net profit for H1 FY26 despite a 2.7% rise in sales, driven by growth in aesthetics and exports. The company faces challenges from regulatory bans on Amalgam products while advancing plans for manufacturing upgrades and a potential acquisition.

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.

Vinyl Group Ltd has reported a robust 49% increase in revenue for the first half of FY26, alongside a significant reduction in net loss, driven by strategic acquisitions and AI integration.

Nexalis Therapeutics reported a widening loss of $1.83 million for 2025, reflecting increased investment in product development and marketing. Despite the loss, the company boosted its cash reserves through equity raises and borrowings.

Excelsior Capital Limited reported a $2.08 million loss for the half-year ending December 2025 as it moves to wind up operations, yet declared a substantial fully franked interim dividend.

TerraCom Limited reported a significant half-year loss amid falling coal prices and production challenges, completing a $56 million capital raise to strengthen its financial position.

Murray Cod Australia Ltd reported a 40% revenue increase to $6.69 million for H1 2026 but swung to a $4.06 million net loss, reflecting significant investments and operational expansion.

RBR Group Limited narrowed its half-year loss to $588,746 as Mozambique LNG project activities resumed, underpinning cautious optimism amid ongoing funding challenges.

Halo Technologies Holdings Ltd posted a $17.4 million loss for 2025, widening from $14.5 million the previous year, as revenue fell 16%. The company completed a $3.9 million rights issue and announced a strategic pivot in its UK operations.

Aumake Limited reported a sharp 45% drop in half-year revenue alongside a 24% increase in net loss, while securing new capital and a major distribution deal to support its pivot in the China market.

Keybridge Capital has posted a $6.14 million loss for the half-year ended 31 December 2024, driven by legacy governance issues and significant legal costs. A new board, appointed following court intervention, is now focused on stabilising the company and pursuing recovery actions.